These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23292897)

  • 1. New prostate cancer drugs hold promise.
    Cancer; 2013 Jan; 119(2):247-8. PubMed ID: 23292897
    [No Abstract]   [Full Text] [Related]  

  • 2. US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun.
    D'Amico AV
    J Clin Oncol; 2014 Feb; 32(4):362-4. PubMed ID: 24344221
    [No Abstract]   [Full Text] [Related]  

  • 3. New agents in the arsenal to fight castrate-resistant prostate cancer.
    Ezzell EE; Chang KS; George BJ
    Curr Oncol Rep; 2013 Jun; 15(3):239-48. PubMed ID: 23440553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A renaissance in the medical treatment of advanced prostate cancer.
    Rove KO; Flaig TW
    Oncology (Williston Park); 2010 Dec; 24(14):1308-13, 1318. PubMed ID: 21294475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards random sequencing or precision medicine in castration-resistant prostate cancer?
    Loriot Y; Fizazi K
    Eur Urol; 2014 Jan; 65(1):37-8. PubMed ID: 24075577
    [No Abstract]   [Full Text] [Related]  

  • 6. [Promising on advanced cancer, several new drugs coming].
    Widmark A; Karlsson CT
    Lakartidningen; 2012 Feb 22-28; 109(8):416-9. PubMed ID: 22509668
    [No Abstract]   [Full Text] [Related]  

  • 7. New therapeutic agents for castration-refractory prostate cancer.
    Patten DY; Sartor O
    Clin Genitourin Cancer; 2009 Aug; 7(2):E4-6. PubMed ID: 19692323
    [No Abstract]   [Full Text] [Related]  

  • 8. Current clinical trials in castrate-resistant prostate cancer.
    Petrylak DP
    Curr Urol Rep; 2011 Jun; 12(3):173-9. PubMed ID: 21533748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic windows and opportunity cost cast upon prostate cancer's fatal shore.
    Goldkorn A; Aparicio AM; Quinn DI
    Ann Oncol; 2013 Jul; 24(7):1717-1720. PubMed ID: 23798673
    [No Abstract]   [Full Text] [Related]  

  • 10. [Novel drugs provide better therapy for prostate cancer].
    Kellokumpu-Lehtinen P; Tammela T
    Duodecim; 2013; 129(9):923-30. PubMed ID: 23786104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in the therapy of castration-resistant prostate cancer: the price of progress.
    Vasani D; Josephson DY; Carmichael C; Sartor O; Pal SK
    Maturitas; 2011 Oct; 70(2):194-6. PubMed ID: 21831545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of docetaxel failures in metastatic castrate-resistant prostate cancer.
    Pal SK; Lewis B; Sartor O
    Urol Clin North Am; 2012 Nov; 39(4):583-91. PubMed ID: 23084533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new era for castrate resistant prostate cancer: a treatment review and update.
    Fong MK; Hare R; Jarkowski A
    J Oncol Pharm Pract; 2012 Sep; 18(3):343-54. PubMed ID: 22343966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes.
    Galsky MD; Small AC; Tsao CK; Oh WK
    CA Cancer J Clin; 2012; 62(5):299-308. PubMed ID: 22535487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Castration refractory prostate cancer: cinderella finally comes to the ball.
    Chowdhury S; Harper P; Powles T
    Onkologie; 2010; 33(12):655-6. PubMed ID: 21124035
    [No Abstract]   [Full Text] [Related]  

  • 16. [2017 ASCO: Complete androgen blockade strikes back].
    Penel N
    Bull Cancer; 2017; 104(7-8):599-601. PubMed ID: 28688745
    [No Abstract]   [Full Text] [Related]  

  • 17. [New hope in the treatment of advanced cancer of the prostate in 2012].
    Massard C
    Bull Cancer; 2012 Jul; 99 Suppl 1():S3. PubMed ID: 23767051
    [No Abstract]   [Full Text] [Related]  

  • 18. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
    Payne H; Bahl A; Mason M; Troup J; De Bono J
    BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The trend toward development of novel agents based on the mechanism of prostate cancer progression].
    Iwasaki K; Obara W; Fujioka T
    Nihon Rinsho; 2011 Jun; 69 Suppl 5():150-4. PubMed ID: 22207961
    [No Abstract]   [Full Text] [Related]  

  • 20. Recent progress in pharmaceutical therapies for castration-resistant prostate cancer.
    Yin L; Hu Q; Hartmann RW
    Int J Mol Sci; 2013 Jul; 14(7):13958-78. PubMed ID: 23880851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.